1-13 of 13
Violeta Serra
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B058: Combination of the PARP1-selective inhibitor AZD5305 with the ATR inhibitor ceralasertib for the treatment of PARPi-resistant cancer

Mark Albertella, Paul Wijnhoven, Annie Demin, Giuditta Illuzzi, Andrea Herencia Ropero, Violeta Serra, Ankur Karmokar, Anna Staniszewska, Alan Lau
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): B058.
https://doi.org/10.1158/1535-7163.TARG-23-B058
Published: 01 December 2023
View article titled, Abstract B058: Combination of the PARP1-selective inhibitor AZD5305 with the ATR inhibitor ceralasertib for the treatment of PARPi-resistant cancer
Journal Articles

Abstract LB_C04: Novel orally bioavailable macrocycles that target cyclin A and B elicit antitumor activity in breast cancer patient-derived xenograft models

Mariana Paes Dias, Li-Fen Liu, Bernard Levin, Cristina Molina, Marta Guzmán, Olga Rodríguez, Evelyn W. Wang, Violeta Serra
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): LB_C04.
https://doi.org/10.1158/1535-7163.TARG-23-LB_C04
Published: 01 December 2023
View article titled, Abstract LB_C04: Novel orally bioavailable macrocycles that target cyclin A and B elicit antitumor activity in breast cancer patient-derived xenograft models
Journal Articles

Abstract P069: GDF15 contributes to the maintenance of the drug-tolerant persister state in cells responding to eribulin

Chiara Bellio, Marta Emperador, Esther Zamora, Violeta Serra, Cristina Saura, Bruce A. Littlefield, Josep Villanueva
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P069.
https://doi.org/10.1158/1535-7163.TARG-21-P069
Published: 01 December 2021
View article titled, Abstract P069: GDF15 contributes to the maintenance of the drug-tolerant persister state in cells responding to eribulin
Journal Articles

Direct CDKN2 Modulation of CDK4 Alters Target Engagement of CDK4 Inhibitor Drugs

Jennifer L. Green, Eric S. Okerberg, Josilyn Sejd, Marta Palafox, Laia Monserrat, Senait Alemayehu, Jiangyue Wu, Maria Sykes, Arwin Aban, Violeta Serra, Tyzoon Nomanbhoy
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (4): 771–779.
https://doi.org/10.1158/1535-7163.MCT-18-0755
Published: 01 April 2019
View article titled, Direct CDKN2 Modulation of CDK4 Alters Target Engagement of CDK4 Inhibitor Drugs
Open the PDF for Direct CDKN2 Modulation of CDK4 Alters Target Engagement of CDK4 Inhibitor Drugs in another window
Journal Articles

Abstract B38: p90RSK mediates resistance to PI3K-pathway inhibitors in breast cancer

Pieter J.A. Eichhorn, Violeta Serra, Celina Garcia-Garcia, Yasir H. Ibrahim, Lumilla Prudkin, Josep-Lluis Parra, Aleix Prat, William C. Hahn, So Young Kim, Jose Baselga
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (7_Supplement): B38.
https://doi.org/10.1158/1538-8514.PI3K14-B38
Published: 06 July 2015
View article titled, Abstract B38: p90RSK mediates resistance to PI3K-pathway inhibitors in breast cancer
Journal Articles

Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors

Rodrigo Dienstmann, Jordi Rodon, Violeta Serra, Josep Tabernero
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2014) 13 (5): 1021–1031.
https://doi.org/10.1158/1535-7163.MCT-13-0639
Published: 05 May 2014
View article titled, Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors
Open the PDF for Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors in another window
Journal Articles

Abstract B106: mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer.

Moshe Elkabets, Sadhna Vora, Dejan Juric, Natasha Morse, Mari Mino-Kenudson, Taru Muranen, Jessica Tao, Ana Bosch Campos, Jordi Rodon, Yasir H. Ibrahim, Violeta Serra, Vanessa Rodrik-Outmezguine, Saswati Hazra, Sharat Singh, Phillip Kim, Cornelia Quadt, Liu Manway, Alan Huang, Neal Rosen, Jeffrey A. Engelman, Maurizio Scaltriti, José Baselga
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): B106.
https://doi.org/10.1158/1535-7163.TARG-13-B106
Published: 01 November 2013
View article titled, Abstract B106: mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer.
Journal Articles

Abstract B117: Analysis of secondary mutations in BRCA1/2 genes as a mechanism of resistance to PM01183 in BRCA-mutation carriers.

Cristina Cruz, Ana Vivancos, Ginevra Caratu, Yasir Ibrahim, Violeta Serra, Judith Balmana
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): B117.
https://doi.org/10.1158/1535-7163.TARG-13-B117
Published: 01 November 2013
View article titled, Abstract B117: Analysis of secondary mutations in <em>BRCA1/2</em> genes as a mechanism of resistance to PM01183 in <em>BRCA</em>-mutation carriers.
Journal Articles

Abstract A8: The EurOPDX consortium: Sharing patient tumor-derived xenografts for collaborative multicentric preclinical trials.

Emilie Vinolo, Elisabetta Marangoni, Violeta Serra, Frederic Amant, Andrea Bertotti, Andrew V. Biankin, Anne-Lise Børresen-Dale, Alejandra Bruna, Eva Budinská, Annette Byrne, Carlos Caldas, David Chang, Robert Clarke, Els Hermans, Manuel Hidalgo, Steven de Jong, Jos Jonkers, Pedro López, Gunhild Mari Mælandsmo, Vlad Popovici, Sergio Roman-Roman, Joan Seoane, Livio Trusolino, Alberto Villanueva
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A8.
https://doi.org/10.1158/1535-7163.TARG-13-A8
Published: 01 November 2013
View article titled, Abstract A8: The EurOPDX consortium: Sharing patient tumor-derived xenografts for collaborative multicentric preclinical trials.
Journal Articles

Abstract C114: Clinical response to a lapatinib-based therapy of a Li-Fraumeni Syndrome patient with a novel HER2-V659E mutation.

Violeta Serra, Ana Vivancos, Xose Puente, Enriqueta Felip, Daniel Silberschmidt, Ginevra Caratù, Josep-Lluis Parra, Leticia De Mattos-Arruda, Judit Grueso, Javier Hernández-Losa, Joaquín Arribas, Ludmila Prudkin, Paolo Nuciforo, Maurizio Scaltriti, Joan Seoane, José Baselga
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C114.
https://doi.org/10.1158/1535-7163.TARG-13-C114
Published: 01 November 2013
View article titled, Abstract C114: Clinical response to a lapatinib-based therapy of a Li-Fraumeni Syndrome patient with a novel HER2-V659E mutation.
Journal Articles

Abstract CN03-04: PI3K pathway inhibitors: How deep should we go?

Rodrigo Dienstmann, Jordi Rodon, Cristina Saura, Teresa Macarulla, Jose Manuel Perez, Maria Alsina, Violeta Serra, Enriqueta Felip, Josep Tabernero
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): CN03-04.
https://doi.org/10.1158/1535-7163.TARG-11-CN03-04
Published: 12 November 2011
View article titled, Abstract CN03-04: PI3K pathway inhibitors: How deep should we go?
Journal Articles

Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer

Maurizio Scaltriti, Violeta Serra, Emmanuel Normant, Marta Guzman, Olga Rodriguez, Alice R. Lim, Kelly L. Slocum, Kip A. West, Varenka Rodriguez, Ludmila Prudkin, José Jimenez, Claudia Aura, José Baselga
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (5): 817–824.
https://doi.org/10.1158/1535-7163.MCT-10-0966
Published: 08 May 2011
View article titled, Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer
Open the PDF for Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract B144: NVP‐BEZ235, a dual inhibitor of PI3K and mTOR, induces MAPK phosphorylation in HER2‐positive cells

Violeta Serra Elizalde, Pieter JA Eichhorn, Maurizio Scaltriti, Ludmila Prudkin, Olga Rodriguez, Marta Guzman, José Baselga
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): B144.
https://doi.org/10.1158/1535-7163.TARG-09-B144
Published: 10 December 2009
View article titled, Abstract B144: NVP‐BEZ235, a dual inhibitor of PI3K and mTOR, induces MAPK phosphorylation in HER2‐positive cells